Source: Tech – South China Morning PostAkeso’s immunotherapy drug allowed half of its patients to go 11.1 months without their condition worsening.Read More
Source: Tech – South China Morning PostAkeso’s immunotherapy drug allowed half of its patients to go 11.1 months without their condition worsening.Read More